We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) announced detailed data from the phase III study – ASCEND – evaluating its BTK inhibitor, Calquence (acalabrutinib), in patients with relapsed or refractory chronic lymphocytic leukemia (“CLL”). Data were presented at the European Hematology Association (“EHA”) annual congress.
In May, the company announced that the study met its primary endpoint of statistically-significant and clinically-meaningful improvement in progression-free survival (“PFS”) in previously-treated CLL patients. The study compared Calquence monotherapy to a combination regimen of Roche (RHHBY - Free Report) /Biogen’s (BIIB - Free Report) CD-20 antibody, Rituxan (rituximab), plus Gilead’s (GILD - Free Report) Zydelig (idelalisib) or Teva’s Treanda (bendamustine).
The latest detailed data from the ASCEND study showed that Calquence reduced the risk of disease progression by 69% compared to Rituxan combination therapy after median follow-up of 16.1 months. The median PFS for the Calquence is yet to be reached compared to 16.5 months for Rituxan combo. Meanwhile, 88% of patients treated with Calquence did not show any disease progression at 12 months compared to 68% for the control arm.
Earlier this month, AstraZeneca announced successful completion of the phase III study – ELEVATE-TN – evaluating Calquence in combination with Roche’s Gazyva in previously-untreated CLL patients. The combination therapy demonstrated statistically significant and clinically meaningful improvement in PFS compared to the chemotherapy-based combo of chlorambucil and Gazyva (standard-of-care medicines).
Calquence is presently marketed for the treatment of relapsed or refractory mantle cell lymphoma (“MCL”). It is being developed in phase III programs for larger CLL indication and AstraZeneca expects to file regulatory applications based on data from the ASCEND and ELEVATE-TN studies later this year to get an approval for CLL. If approved for CLL, this would definitely help AstraZeneca gain access to a broader patient population and boost sales of this promising drug.
Shares of AstraZeneca have gained 4.4% so far this year compared with the industry’s increase of 2.1%.
In a separate press release, the company announced data from the phase IIIb study, DIALIZE, evaluating Lokelma for the treatment of hyperkalemia in patients with end-stage renal disease (“ESRD”) on hemodialysis. Data from the study showed that 41.2% of patients maintained pre-dialysis normal potassium levels on at least three out of four dialysis treatments compared to 1% for placebo. Results demonstrate the potential of Lokelma in normalizing potassium levels in between dialysis sessions. This may lead to better prospects for the drug in hyperkalemia patients with ESRD, a patient population with high unmet treatment need.
The drug is already approved for hyperkalemia, a serious condition characterized by elevated potassium levels in the blood.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
Image: Bigstock
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
AstraZeneca (AZN - Free Report) announced detailed data from the phase III study – ASCEND – evaluating its BTK inhibitor, Calquence (acalabrutinib), in patients with relapsed or refractory chronic lymphocytic leukemia (“CLL”). Data were presented at the European Hematology Association (“EHA”) annual congress.
In May, the company announced that the study met its primary endpoint of statistically-significant and clinically-meaningful improvement in progression-free survival (“PFS”) in previously-treated CLL patients. The study compared Calquence monotherapy to a combination regimen of Roche (RHHBY - Free Report) /Biogen’s (BIIB - Free Report) CD-20 antibody, Rituxan (rituximab), plus Gilead’s (GILD - Free Report) Zydelig (idelalisib) or Teva’s Treanda (bendamustine).
The latest detailed data from the ASCEND study showed that Calquence reduced the risk of disease progression by 69% compared to Rituxan combination therapy after median follow-up of 16.1 months. The median PFS for the Calquence is yet to be reached compared to 16.5 months for Rituxan combo. Meanwhile, 88% of patients treated with Calquence did not show any disease progression at 12 months compared to 68% for the control arm.
Earlier this month, AstraZeneca announced successful completion of the phase III study – ELEVATE-TN – evaluating Calquence in combination with Roche’s Gazyva in previously-untreated CLL patients. The combination therapy demonstrated statistically significant and clinically meaningful improvement in PFS compared to the chemotherapy-based combo of chlorambucil and Gazyva (standard-of-care medicines).
Calquence is presently marketed for the treatment of relapsed or refractory mantle cell lymphoma (“MCL”). It is being developed in phase III programs for larger CLL indication and AstraZeneca expects to file regulatory applications based on data from the ASCEND and ELEVATE-TN studies later this year to get an approval for CLL. If approved for CLL, this would definitely help AstraZeneca gain access to a broader patient population and boost sales of this promising drug.
Shares of AstraZeneca have gained 4.4% so far this year compared with the industry’s increase of 2.1%.
In a separate press release, the company announced data from the phase IIIb study, DIALIZE, evaluating Lokelma for the treatment of hyperkalemia in patients with end-stage renal disease (“ESRD”) on hemodialysis. Data from the study showed that 41.2% of patients maintained pre-dialysis normal potassium levels on at least three out of four dialysis treatments compared to 1% for placebo. Results demonstrate the potential of Lokelma in normalizing potassium levels in between dialysis sessions. This may lead to better prospects for the drug in hyperkalemia patients with ESRD, a patient population with high unmet treatment need.
The drug is already approved for hyperkalemia, a serious condition characterized by elevated potassium levels in the blood.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>